DESCRIPTION: The House Judiciary Subcommittee on Antitrust held a hearing to examine competition problems in the development and delivery of health care services and products, and the resulting harm to consumers and the marketplace. CR submitted a letter encouraging the Subcommittee’s bipartisan work, highlighting some recent successes, and reaffirming our support for three bills that would help stop anticompetitive practices by brand name prescription drug makers to prolong their monopoly profits by blocking more affordable generic alternatives from entering the market to give consumers choice.